Sincalide Injection

As an artificially synthesized analogue of cholecystokinin octapeptide (CCK-8), Sincalide Injection is distinctly classified not as a therapeutic drug intended for conventional disease treatment, but rather as a specialized tool reagent uniquely positioned within the clinical diagnostic landscape. Its fundamental utility is derived from the capacity to elicit precise and targeted pharmacological effects that closely mimic endogenous physiological stimulation, thereby providing objective, quantifiable, and critically important diagnostic data for the comprehensive functional evaluation of the gallbladder, exocrine pancreas, and associated biliary system. By doing so, Sincalide effectively addresses a significant and long-standing diagnostic gap, as conventional morphological imaging techniques-such as ultrasound, computed tomography, or magnetic resonance cholangiopancreatography-while excellent for visualizing structural abnormalities, are inherently limited in their ability to assess dynamic physiological function.

Our Products

​

Sincalide COA

Certificate of Analysis
Compound name	Sincalide
Grade	Pharmaceutical grade
CAS No.	25126-32-3
Quantity	39g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090088
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.54%
Loss on drying	≤1.0%	0.42%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.98%
Single impurity	<0.8%	0.52%
Total microbial count	≤750cfu/g	95
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	500ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Consequently, this diagnostic agent has evolved into an indispensable and integral component of the modern digestive function testing paradigm, enabling clinicians to move beyond static anatomical observation toward a more holistic understanding of organ performance. This article will briefly elucidate the fundamental material properties and pharmacological basis of Sincalide Injection, followed by a focused and detailed analysis of its core diagnostic functions, specific clinical applications, and unique advantages over alternative approaches, ultimately presenting a comprehensive overview of the significant and often irreplaceable value this specific diagnostic reagent brings to contemporary gastroenterology practice.

As a structurally modified synthetic homolog of endogenous cholecystokinin octapeptide, sincalide has a highly conserved amino acid sequence arrangement with natural CCK-8. Only through chemical modification of the terminal group, it avoids the weakness of natural peptides that are easily degraded rapidly, significantly improving metabolic stability in vivo. Its molecular spatial conformation can accurately match the binding pocket of cholecystokinin A (CCK-A) receptor, and its selective affinity for CCK-A receptor is much higher than that for CCK-B receptor, laying a molecular foundation for its organ specific pharmacological effects; At the same time, its rigid peptide chain skeleton reduces non-specific conformational fluctuations, improving the accuracy of target receptor recognition and minimizing the probability of off target effects.

Compared with natural cholecystokinin, after structural optimization, the plasma stability of sincalide injection is significantly improved after intravenous administration, and there is no obvious non-specific plasma protein binding, ensuring the controllability and repeatability of its pharmacological effects. Its truncated peptide chain structure retains the core active domain of CCK-8 and eliminates redundant molecular fragments that may cause adverse physiological reactions, making it an ideal reagent suitable for clinical diagnostic needs.

The pharmacological effects of sincalide are strictly limited to the digestive organs. By activating CCK-A receptors to trigger intracellular signaling cascades, it regulates the motility and secretion functions of the gastrointestinal tract. Its core uses revolve around the clinical diagnosis of digestive organ function, mainly covering three major scenarios. The specific application logic and value of each scenario are as follows:

(I)Quantitative assessment of gallbladder function

This is the most core clinical application scenario of sincalide, which provides accurate quantitative indicators for gallbladder function evaluation by specifically stimulating gallbladder smooth muscle contraction and combining with liver and gallbladder nuclear imaging (such as HIDA scanning).

The specific application points include:

• By intravenous injection, the smooth muscle of the gallbladder can be induced to contract in a gradient and promote bile emptying. Combined with imaging technology, the ejection fraction of the gallbladder can be accurately calculated to determine whether the gallbladder contraction function is within the normal range, providing objective basis for the diagnosis of diseases such as gallbladder motility disorders and chronic non calculous cholecystitis;
• -Quantitative functional indicators can be provided for subclinical conditions such as insufficient gallbladder motility and delayed emptying, filling the gap of morphological examinations such as ultrasound and CT in capturing functional abnormalities and helping to detect potential gallbladder functional lesions early;
• -It can be used for follow-up evaluation of functional recovery after gallbladder surgery, providing reference for adjusting clinical diagnosis and treatment plans by dynamically monitoring the recovery of gallbladder contraction function.

(II)Non invasive detection of pancreatic exocrine function

Sincalide injection can specifically activate the CCK-A receptor of pancreatic acinar cells, promote the synthesis and secretion of pancreatic juice and digestive enzymes, and become a core stimulating reagent for non-invasive detection of pancreatic exocrine function. Its specific applications are as follows:

• As a core reagent for pancreatic function stimulation testing, the reserve function of pancreatic exocrine cells can be evaluated by detecting the secretion of pancreatic juice, the activity of pancreatic amylase, pancreatic lipase and other digestive enzymes after administration, which can be used for early screening of chronic pancreatitis, pancreatic dysfunction and other diseases;
• Compared with invasive detection methods such as cholangiopancreatography, its non-invasive nature can effectively avoid the risk of complications such as infection and bleeding, improve patient tolerance, and is suitable for routine functional screening of outpatient and inpatient patients;
• It can assist in distinguishing pancreatic exocrine dysfunction from other digestive system diseases, providing important reference for clinical differential diagnosis and reducing the probability of misdiagnosis and missed diagnosis.

(III)Assisted optimization of biliary imaging

Xincalide can improve the clarity of biliary imaging by regulating biliary dynamics, providing auxiliary support for morphological and functional diagnosis of the biliary system. Its specific functions include:

• Inducing moderate relaxation of the Audi sphincter, synchronously coordinating gallbladder contraction and biliary emptying, reducing the interference of bile stasis on extrahepatic bile duct imaging, significantly improving the imaging clarity of magnetic resonance cholangiopancreatography (MRCP), endoscopic retrograde cholangiopancreatography (ERCP) and other examinations;
• Eliminating imaging artifacts caused by bile stasis, helping to more accurately distinguish biliary obstructive lesions from functional biliary motility disorders in clinical practice, and reducing the misdiagnosis rate of functional biliary diseases;
• Can assist in evaluating the patency and functional recovery of the biliary tract after surgery, providing auxiliary evidence for postoperative diagnosis, treatment, and follow-up.

Compared to traditional digestive organ function diagnostic reagents, Xincalide has demonstrated unique advantages in adapting to clinical diagnostic needs through its optimized structure and pharmacological properties, which can be summarized as follows:

• Excellent safety and good tolerability, with no significant organ toxicity at standard diagnostic doses, suitable for patients of all ages, and no need for routine preoperative allergy testing; Occasional adverse reactions are often brief and mild gastrointestinal discomfort or facial flushing, which are physiological extensions of the pharmacological effects of the target organ and can be relieved on their own without intervention, and there are no long-term safety hazards;
• The metabolic pathway is simple and without accumulation risk, without the need for first pass metabolism through the liver. It is mainly excreted in the form of intact peptide chains through the kidneys, with a short residence time in the body and no generation of active metabolites. The pharmacological effect is terminated synchronously with drug clearance, making it suitable for diagnostic use at a single dose.

• The effect is precise and time sensitive, and the pharmacological effect of the target organ can be triggered within minutes after intravenous administration. The peak effect occurs 10-15 minutes after administration, which is highly compatible with the rapid turnover needs of clinical diagnostic examinations and can effectively improve diagnostic efficiency;
• Highly specific, it only acts on CCK-A receptors and its pharmacological effects are strictly limited to digestive organs such as gallbladder, pancreas, and biliary tract. There is no obvious systemic non-specific response, which can accurately avoid interference with other organs and ensure the accuracy of diagnostic results;
• The administration method is convenient and the dosage is controllable, requiring only intravenous infusion or intravenous push injection, without the need for complex administration procedures; The dosage and pharmacological effects are linearly correlated, and the dosage can be flexibly adjusted according to the individual patient's situation and diagnostic needs to achieve personalized diagnostic stimulation.

In summary, as a structurally optimized synthetic analog of cholecystokinin octapeptide (CCK-8), Sincalide embodies its core value by delivering precise, safe, and highly efficient diagnostic support for the assessment of digestive organ function.

By enabling the quantitative evaluation of gallbladder contractility and exocrine pancreatic function, while also serving as an auxiliary tool to optimize biliary imaging, it effectively addresses a critical gap where traditional morphological examinations often fall short in capturing functional dynamics. Its distinct advantages-including strong biological specificity, an excellent safety profile, and favorable pharmacokinetic timeliness-position it as an indispensable reagent in the clinical diagnostic toolkit of modern gastroenterology. Ultimately, Sincalide provides robust technical support for the early detection, accurate diagnosis, and standardized follow-up of a wide spectrum of disorders related to digestive organ dysfunction, thereby underscoring its irreplaceable and unique value in the field of clinical diagnostics.

• Is sincalide the same as CCK?

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8.

• What is the mechanism of action of Sincalide?

The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Sincalide also stimulates pancreatic secretion and intestinal motility causing pyloric contraction and slows gastric emptying.

Hot Tags: sincalide injection, China sincalide injection manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, glucagon emergency kit 1 mg, glp1 shot, etelcalcetide structure